BBNX Stock Analysis: Beta Bionics, Common Stock | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 747m USD | 12M Return: 25.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.7M
Qual. Beats: 0
Rev. Trend: 94.6%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Beta Bionics, Inc. (NASDAQ: BBNX) is a commercial-stage medical device company focused on developing solutions for insulin-requiring individuals with diabetes. Its flagship product, the iLet Bionic Pancreas, is an automated insulin delivery device approved for type 1 diabetes in patients aged six and older. The company is also advancing a pipeline that includes a tubeless Patch Pump, a bihormonal iLet combining insulin and glucagon delivery, and an iLet system for insulin-dependent type 2 diabetes.
Operating within the health care equipment subsector, Beta Bionics is part of the broader diabetes management market, where automated insulin delivery (AID) systems are increasingly viewed as a standard of care for intensive insulin therapy. Strategic partnerships with Xeris Biopharma for a pump-compatible glucagon formulation and with Abbott Diabetes Care for an integrated automated insulin delivery system support its development efforts.
Headquartered in Irvine, California, and incorporated in 2015, Beta Bionics completed its initial public offering in early 2025 and is classified as a small-cap stock. Its business model centers on commercializing proprietary wearable insulin delivery technology for both pediatric and adult diabetes populations.
- iLet Bionic Pancreas adoption drives revenue growth
- FDA approval progress for Patch Pump and Bihormonal iLet pipeline
- Competition from Tandem and Insulet intensifies in automated insulin delivery
| Net Income: -66.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA -2.50 > 1.0 |
| NWC/Revenue: 203.9% < 20% (prev 351.5%; Δ -147.5% < -1%) |
| CFO/TA -0.18 > 3% & CFO -54.8m > Net Income -66.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.4m) vs 12m ago 44.67% < -2% |
| Gross Margin: 57.15% > 18% (prev 53.93%; Δ 3.22% > 0.5%) |
| Asset Turnover: 34.32% > 50% (prev 20.66%; Δ 13.66% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.74 (Total Current Assets 248.0m - Total Current Liabilities 23.2m) / Total Assets 304.4m |
| B: -1.29 (Retained Earnings -391.8m / Total Assets 304.4m) |
| C: -0.21 (EBIT TTM -66.4m / Avg Total Assets 321.2m) |
| D: 8.18 (Book Value of Equity 271.2m / Total Liabilities 33.2m) |
| Altman-Z'' = 7.84 = AAA |
| DSRI: 1.03 (Receivables 17.9m/11.0m, Revenue 110.2m/69.8m) |
| GMI: 0.94 (GM 53.93% / 57.15%) |
| AQI: 0.69 (AQ_t 0.13 / AQ_t-1 0.19) |
| SGI: 1.58 (Revenue 110.2m / 69.8m) |
| TATA: -0.04 (NI -66.4m - CFO -54.8m) / TA 304.4m) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 17.03 with a total of 650,462 shares traded. Over the past week, the price has changed by +1.61%, over one month by +24.13%, over three months by +92.21% and over the past year by +25.59%.
Current recommended Stop Loss: 14.60 (which is 14.3% or 2.5 ATR below the current price).
Beta Bionics, Common Stock has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy BBNX.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.2 | 12.6% |
P/S = 6.7749
P/B = 2.7469
Revenue TTM = 110.2m USD
EBIT TTM = -66.4m USD
EBITDA TTM = -63.5m USD
Long Term Debt = 5.07m USD (estimated: total debt 6.91m - short term 1.84m)
Short Term Debt = 1.84m USD (from shortTermDebt, last quarter)
Debt = 6.91m USD (from shortLongTermDebtTotal, last quarter) (leases 6.91m already included)
Net Debt = -192.6m USD (calculated: Debt 6.91m - CCE 199.5m)
Enterprise Value = 554.2m USD (746.9m + Debt 6.91m - CCE 199.5m)
Interest Coverage Ratio = unknown (Ebit TTM -66.4m / Interest Expense TTM 0.0)
EV/FCF = -9.07x (Enterprise Value 554.2m / FCF TTM -61.1m)
FCF Yield = -11.03% (FCF TTM -61.1m / Enterprise Value 554.2m)
FCF Margin = -55.45% (FCF TTM -61.1m / Revenue TTM 110.2m)
Net Margin = -60.27% (Net Income TTM -66.4m / Revenue TTM 110.2m)
Gross Margin = 57.15% ((Revenue TTM 110.2m - Cost of Revenue TTM 47.2m) / Revenue TTM)
Gross Margin QoQ = 59.50% (prev 58.98%)
Tobins Q-Ratio = 1.82 (Enterprise Value 554.2m / Total Assets 304.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.91m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -52.5m (EBIT -66.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.69 (Total Current Assets 248.0m / Total Current Liabilities 23.2m)
Debt / Equity = 0.03 (Debt 6.91m / totalStockholderEquity, last quarter 271.2m)
Debt / EBITDA = 3.03 (negative EBITDA) (Net Debt -192.6m / EBITDA -63.5m)
Debt / FCF = 3.15 (negative FCF - burning cash) (Net Debt -192.6m / FCF TTM -61.1m)
Total Stockholder Equity = 288.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.68% (Net Income -66.4m / Total Assets 304.4m)
RoE = -23.00% (Net Income TTM -66.4m / Total Stockholder Equity 288.8m)
RoCE = -22.61% (EBIT -66.4m / Capital Employed (Equity 288.8m + L.T.Debt 5.07m))
RoIC = -18.91% (negative operating profit) (NOPAT -52.5m / Invested Capital 277.6m)
WACC = 12.75% (E(746.9m)/V(753.8m) * Re(12.87%) + D(6.91m)/V(753.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 59.81 | Cagr: 143.0%
[DCF] Fair Price = unknown (Cash Flow -61.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.14 | # QB: 0
Revenue Correlation: 94.60 | Revenue CAGR: 189.1% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.55 | Chg30d=+0.00% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.53 | Chg30d=+0.00% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-2.11 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=-52.9% | GrowthRev=+33.3%
EPS next Year (2027-12-31): EPS=-2.39 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=-13.5% | GrowthRev=+35.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)